NPPB and diabetes mellitus: In the case of the FDS2, we were able to adjust for key variables such as race/ethnicity, socioeconomic characteristics, diabetes-specific management and complications, use of cardiovascular risk-reducing therapies, and novel biomarkers including serum NT-proBNP and hsCRP.